Clinical Trial: Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC

U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07403435) titled 'Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC' on Sept. 08, 2025.

Brief Summary: This study includes patients with resectable esophageal squamous cell carcinoma who will undergo local radiotherapy (PTV: 1.5Gy Bid, for 5 days), followed by neoadjuvant treatment with Serplulimab combined with cisplatin and paclitaxel for three cycles. Afterward, they will undergo surgery. Postoperatively, researchers will select adjuvant treatment plans based on the patients' conditions.

Study Start Date: Feb. 15

Study Type: INTERVENTIONAL

Condition: Esophageal Squamous Cell Carci...